Pierre Tariot, M.D.

Academic and Clinical Appointments

Professor of Psychiatry (with unlimited tenure), of Medicine, of Neurology, and of Aging and Developmental Biology.

Director of Psychiatry
Program in Neurobehavioral Therapeutics
Monroe Community Hospital

Contact Information

Education

Research
Focus and
Interests

1. Alzheimer’s disease and related dementia’s
2. Clinical trials
3. Nursing home research

Professional Overview

Dr. Tariot is a Phi Beta Kappa graduate of Amherst College who attended the University of Rochester School of Medicine and Dentistry. He completed residencies in Internal Medicine and Psychiatry at the University of Wisconsin in Madison, Wisconsin, and is Board Certified in both specialties. He served as a Medical Staff Fellow and then Senior Staff Fellow at the Intramural Research Program of the National Institute of Mental Health. Since 1986, he has been at the University of Rochester Medical Center, where he is now Professor of Psychiatry, Medicine, Neurology, and Aging and Developmental Biology. Several titles describe his work at the University of Rochester. He is Co-Director of the University Geriatric Neurology and Psychiatry Clinic, Director of Psychiatry at Monroe Community Hospital and Director of the University of Rochester component of the Alzheimer’s Disease Cooperative Study, funded by the National Institute on Aging. He is a Fellow of the Gerontological Society of America, a Distringuished Fellow of the American Psychiatric Association, and a member of the American College of Neuropsychopharmacology. Dr. Tariot has investigated, and lectured extensively on, multiple aspects of diagnosis and therapy for dementia and Alzheimer’s disease, recognition and management of behavioral disturbances in long-term care settings, and treatment of depression in the elderly. He has published over 150 papers on these topics. He served as the Chair of the Behavioral Pathology Committee of the National Institute on Aging’s Consortium to Establish a Registry for Alzheimer’s Disease. He has earned several awards for his research, including the American Geriatrics Society New Investigator Award for Neuroscience, an NIMH Geriatric Mental Health Academic Award, and Fellowship in the Gerontological Society of America. Dr. Tariot’s research affiliations include the National Institute of Mental Health, the New York State Department of Health, the National Institute on Aging, and the Alzheimer’s Association.

Selected Publications

Mulnard RA, Cotman CW, Kawas C., Van Dyck CH, Sano M, et al: Estrogen Replacement Therapy for Treatmentof Mild to Moderate Alzheimer’s Disease: A 1-year Randomized Controlled Trial. (P. Tariot, Safety Monitoring Committee). JAMA 283: 1007-1015, 2000.

Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, Thal LJ, for the Members of the Alzheimer’s Disease Cooperative Study (P. Tariot, site PI). A randomized controlled trial of prednisone in Alzheimer's disease. Neurology 54(3): 588-93, 2000.

Greene Y, Tariot PN, Wishart H, Cox C, Holt CJ, Schwid S: A 12-Week, Open Trial of DonepezilHydrochloride in Patients with Multiple Sclerosis and Associated Cognitive Impairment. J ClinicalPsychopharmacology 20 (3): 350-356, 2000.

Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Parys W, Ding C and the Galantamine USA-10 Study Group. A 5-month, randomized, placebo-controlled trial of galantamine in Alzheimer’s disease. Neurology 54: 2269-2276, 2000.

Tariot PN, Salzman C, Yeung PP, Pultz J, Rak IW: Long-term Use of the Antipsychotic Quetiapine in Elderly Patients with Psychotic Disorders. Clinical Therapeutics 22 (9): 1069-1084, 2000.

Teri L, Logsdon RG, Peskind E, Raskind M, Weiner, MF, Trachtenberg RE, Foster NL, Schneider LS,Sano M, Whitehouse P, Tariot P, Mellow AM, Auchus AP, Grundman M Thomas RG, Schafer K, Thal LJ: Treatment of Agitation in AD: A Randomized, Placebo-Controlled Clinical Trial. Neurology 55: 12711278, 2000.

Yeung PP, Tariot PN, Schneider LS, Salzman C, Rak IW: Quetiapine for Elderly Patients with Psychotic Disorders. Psychiatric Annals 30(3): 197-201, 2000.

Porsteinsson AP, Tariot PN: Nursing Homes and Long Term Care. In Neurodegenerative Dementia: Clinical Features and Pathological Mechanisms. C. Clark, J Trojanowski, editors, McGraw Hill, New York, 455-464, 2000.

Tariot PN, Porsteinsson AP, Ryan JM: Anticonvulsants to Treat Agitation in Dementia. InternationalPsychogeriatrics, vol. 12 (supp 1) 237-244, 2000.

Tariot PN, Porsteinsson AP, Ryan JM. Efficacy and Tolerability of Carbamazepine in Dementia.Research and Practice in Alzheimer’s Disease, 13: 279-284, 2000.

Rosenquist K, Tariot PN, Loy R: Treatment for Behavioral and Psychological Symptoms in Alzheimer’s Disease and other Dementias. In Dementia, 2nd edition, D Ames, A Burns, J O’Brien (eds), Chapman & Hall, London, chapter 45 571-601, 2000.

Tariot PN, Jakimovich L, Noviasky J, Erb R: Treating Aggression in Patients with Dementia. CMEMonograph, copyright ABcomm, Inc., Champaign, IL, 2000.

Tariot PN: Alzheimer’s Disease is Treatable. Maji M, Sartorius N, eds. In WPA Series: Evidence andExperience in Psychiatry vol. 3, Dementia. Wiley & Sons, Chichester, 240-243, 2000.

Ryan JM, Duffy CJ, Tariot PN: Hemi-Inattention Presenting as Homonymous Hemianopsia in Early Dementia. J. Neuropsychiatry Clin Neurosciences 12: 413-414, 2000.

Loy R, Applegate C, Joseph S, Tariot PN: Protective Effects of Valproate on Seizure Threshold and Hippocampal Neurogenesis Following Flurothyl Kindling. Soc. Neurosci. Abst. 26, 1781, 2000.

Porsteinsson AP, Tariot PN., Erb R, Cox C, Smith E, Jakimovich L, Noviasky J, Kowalski N, Holt C, Irvine C: Placebo- Controlled Study of Divalproex Sodium for Agitation in Dementia. Am J Geriatr Psychiatry 9: 58-66, 2001.

Tariot PN, Schneider L, Mintzer J, Cutler A, Cunningham M, Thomas J, Somerville K: Safety and Tolerability of Divalproex Sodium for the Treatment of Signs and Symptoms of Mania in Elderly Patients with Dementia: Results of a Double-Blind, Placebo-Controlled Trial. Current Therapeutic Research 62 (1): 51-67, 2001.

The Parkinson Study Group: A randomized, controlled trial of remacemide for motor fluctuations in Parkinson’s disease. Neurology 56: 455-462, 2001 (Tariot P. Chairman, Safety Monitoring Committee).

Tariot PN, Cummings JL, Katz IR, Mintzer, J, Perdomo CA, Schwam EM, Whalen E, and the Donepezil Nursing Home Study Investigators Group. A Randomized, Double-blind, Placebo-controlled study of the Efficacy and Safety of Donepezil in Patients with Alzheimer’s Disease in the Nursing Home Setting. J Am Geriatr Soc 49:1590-1599, 2001

Tariot P, Winblad B: Galantamine, A Novel Treatment for Alzheimer's Disease: A Review of Long-term Benefits to Patients and Caregivers. In Alzheimer’s Disease: Advances in Etiology, Pathogenesis and Therapeutics. Khalid Iqbal, Sangram S. Sisodia, Bengt Winblad (eds). John Wiley & Sons, LTD, England, 66: 707-723,2001.

Tariot PN, Ryan JM, Porsteinsson AP, Loy R: Long-Term Treatment: Effects on Cognition. Alzheimer’s Disease, suppl to Clinical Geriatrics, 13-18, March, 2001.

Tariot PN, Ryan JM, Porsteinsson AP, Schneider LS: Pharmacologic Treatment for Behavioral Symptoms of Alzheimer's Disease. Clinics in Geriatric Medicine. Saunders WB, Galasko D (eds), 17(2): 359-376, 2001.

Ryan JM, Loy R, Tariot PN: Impact of Molecular Medicine on Neuropsychiatry: The Clinician’s Perspective. Current Psychiatry Reports 3:355-360, 2001.

Tariot PN: Maintaining cognitive function in Alzheimer's disease: how effective are current treatments? Alzheimer's Disease Assoc Dis vol (15) suppl (1), S26-S33, 2001.

Schneider LS, Tariot PN, Lyketsos CG, Dagerman KS, Davis KL, Davis S, Hsiao JK, Jeste DV, Katz IR, Olin JT, Pollock BG, Rabins PV, Small GW, Lebowitz B, Lieberman JA: National Institute of Mental Health Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) - Alzheimer’s Disease Trial Methodology. Am J Geriatr Psychiatry, 9:346-360, 2001.

Tariot P: Current Status and New Developments with Galantamine in the Treatment of Alzheimer's Disease. Expert Opinion in Pharmacotherapy 2(12), 2027-2049, 2001.

Tariot PN: Special Considerations in the Use of Antipsychotics in the Elderly. Annals of Long-Term Care, Vol.9 #11, 11/2001.

Profenno L, Loy R, Ryan JM, Tariot P, Federoff HJ, Coleman PD: Preliminary Expression Analysis of Valproate-Regulated Serum Proteins in Alzheimer’s Disease Using Seldi Protein Chips. Soc. Neurosci Abs. 27, 2001.

Loy R, , O’Banion MK, Joseph S, Tariot PN, Applegate C: Cox-1 and Cox-2 Induction in Mice Following Flurothyl Kindling. Soc. Neurosci Abs. 27, 2001.

Winblad B, Brodaty H, Gauthier S, Morris JC, Orgogozo JM, Rockwood K, Schneider L, Takeda M, Tariot P, Wilkinson D: Pharmacotherapy of Alzheimer's disease: Is there a need to redefine treatment success? International Journal of Geriatric Psychiatry 16: 653-666, 2001.

Evidence-Based Dementia: A Practical Guide to Diagnosis and Management. Qizilbash N, Schneider L, Chui H, Tariot P, Brodaty H, Kaye J, Erkinjuntti T eds. Blackwell Science Ltd., Oxford, 2002.

Tariot PN: VI Treating Non-Cognitive Problems: Section Editor, 671-722. VI.1 Introduction, 671-674; VI.2.4 Anticonvulsants, 682-686; VI.2.5 Other Classes of Psychotropics in Dementia, 686-694; VI.3.3 Agitation, 705-707; VI.4 Summary, Practical Recommendations, and Opinions, 720-722, in: Evidence-Based Dementia: A Practical Guide to Diagnosis and Management. Qizilbash N, Schneider L, Chui H, Tariot P, Brodaty H, Kaye J, Erkinjuntti T eds. Blackwell Science Ltd., Oxford, 2002.Ismail MS, Tariot: Part I Alzheimer’s Disease: Bridging the Gap Between Clinical Studies and Clinical Practice. Practical Neurology, 30-35, August, 2002.

Ismail MS, Tariot: Part II Alzheimer’s Disease: A Step-by-Step Approach to Clinical Diagnosis & Treatment. Practical Neurology, , 25-29, September, 2002.

Tariot PN, Ismail MS: Cholinesterase Inhibitors. The Practical Guide to Therapeutic Drugs (Supplement to Practical Neurology), 47-49, September 2002.

Tariot PN, Loy R, Ryan JM, Porsteinsson A, Ismail MS: Mood stabilizers in Alzheimer’s disease: symptomatic and neuroprotective rationales. Advanced Drug Delivery Reviews 54, 1567-1577, 2002.

Tariot PN, Schneider L, Katz I, Mintzer J, Street J: Quetiapine in nursing home residents with Alzheimer’s dementia and psychosis. Am J Geriatr Psychiatry 10:2, Supplement 1, 93, 2002.

Tariot PN, Kershaw P: Galantamine produces long-term cognitive benefits in patients with Alzheimer’s disease. Am J Geriatr Psychiatry 10:2, Supplement 1, 93-94, 2002.

Olin JN, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, Bruce ML, Caine ED, Cummings JL, Devanand DP, Jeste DV, Lyketsos CG, Lyness JM, Rabins PV, Reynolds CF, Rovner BW, Steffens DC, Tariot PN, Lebowitz BD: National Institute of Mental Health - Provisional Diagnostic Criteria for Depression of Alzheimer's Disease. Am J Geriatr Psychiatry, 10: 125-128, 2002.

Tariot PN, Loy R, Ryan JM, Manji H, Porsteinsson AP, Ismail S: Mood Stabilizers in Alzheimer's Disease: Symptomatic and Neuroprotective Rationales. Advanced Drug Delivery Review, Berislav Zlokovic (eds.) 54:12, 1567-1577.

Tariot PN, Jakimovich L: Donepezil Use for Moderate to Severe Alzheimer’s Disease - A Case Study from a Long-Term Care Facility. Annals of Long-Term Care: Clinical Care and Aging. (in press).

Kieburtz K and the Parkinson Study Group: The COMT Inhibitor Entacopone Increases on Time in Levodopa - Treated Parkinson’s Disease Patients with Motor Fluctuations (Tariot P, Chairman, Safety Monitoring Committee). Annals of Neurology (in press).

Holloway R and the Parkinson Study Group. A Randomized Controlled Trial Comparing the Agonist Pramipexole with Levodopa as Initial Dopaminergic Therapy in Parkinson’s Disease (P Tariot, Chairman, Safety Monitoring Committee) (JAMA - in press)

Pertinent Web Links

Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT)

National Institute of Mental Health Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE)